| Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity M Soethoudt, U Grether, J Fingerle, TW Grim, F Fezza, L De Petrocellis, ... Nature communications 8 (1), 13958, 2017 | 346 | 2017 |
| NF‐κB activation in astrocytes drives a stage‐specific beneficial neuroimmunological response in ALS N Ouali Alami, C Schurr, F Olde Heuvel, L Tang, Q Li, A Tasdogan, ... The EMBO journal 37 (16), e98697, 2018 | 162 | 2018 |
| Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes A Bénardeau, J Benz, A Binggeli, D Blum, M Boehringer, U Grether, ... Bioorganic & Medicinal Chemistry Letters 19 (9), 2468-2473, 2009 | 154 | 2009 |
| An Oxidation‐Labile Traceless Linker for Solid‐Phase Synthesis F Stieber, U Grether, H Waldmann Angewandte Chemie International Edition 38 (8), 1073-1077, 1999 | 131 | 1999 |
| Selective Photoaffinity Probe That Enables Assessment of Cannabinoid CB2 Receptor Expression and Ligand Engagement in Human Cells M Soethoudt, SC Stolze, MV Westphal, L Van Stralen, A Martella, ... Journal of the American Chemical Society 140 (19), 6067-6075, 2018 | 105 | 2018 |
| Structure-based design of indole propionic acids as novel PPARα/γ co-agonists B Kuhn, H Hilpert, J Benz, A Binggeli, U Grether, R Humm, HP Märki, ... Bioorganic & medicinal chemistry letters 16 (15), 4016-4020, 2006 | 88 | 2006 |
| Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties HGF Richter, GM Benson, KH Bleicher, D Blum, E Chaput, N Clemann, ... Bioorganic & medicinal chemistry letters 21 (4), 1134-1140, 2011 | 87 | 2011 |
| An enzyme‐labile safety catch linker for synthesis on a soluble polymeric support U Grether, H Waldmann Chemistry–A European Journal 7 (5), 959-971, 2001 | 86 | 2001 |
| Goods and bads of the endocannabinoid system as a therapeutic target: lessons learned after 30 years M Maccarrone, V Di Marzo, J Gertsch, U Grether, AC Howlett, T Hua, ... Pharmacological reviews 75 (5), 885-958, 2023 | 82 | 2023 |
| Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice ED Mock, M Mustafa, O Gunduz-Cinar, R Cinar, GN Petrie, V Kantae, X Di, ... Nature chemical biology 16 (6), 667-675, 2020 | 79 | 2020 |
| Discovery of a high affinity and selective pyridine analog as a potential positron emission tomography imaging agent for cannabinoid type 2 receptor R Slavik, U Grether, A Müller Herde, L Gobbi, J Fingerle, C Ullmer, ... Journal of medicinal chemistry 58 (10), 4266-4277, 2015 | 79 | 2015 |
| Novel triazolopyrimidine‐derived cannabinoid receptor 2 agonists as potential treatment for inflammatory kidney diseases M Nettekoven, JM Adam, S Bendels, C Bissantz, J Fingerle, U Grether, ... ChemMedChem 11 (2), 179-189, 2016 | 68 | 2016 |
| Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes HGF Richter, GM Benson, D Blum, E Chaput, S Feng, C Gardes, ... Bioorganic & medicinal chemistry letters 21 (1), 191-194, 2011 | 68 | 2011 |
| Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors M Dietz, P Mohr, B Kuhn, HP Maerki, P Hartman, A Ruf, J Benz, U Grether, ... ChemMedChem 7 (6), 1101-1111, 2012 | 64 | 2012 |
| Indazole or 4, 5, 6, 7-tetrahydro-indazole derivatives GM Benson, K Bleicher, U Grether, B Kuhn, H Richter, S Taylor US Patent 8,008,505, 2011 | 62 | 2011 |
| Phenyl derivatives, their manufacture and use as pharmaceutical agents J Ackermann, J Aebi, A Binggeli, U Grether, G Hirth, B Kuhn, HP Maerki, ... US Patent 7,115,611, 2006 | 60 | 2006 |
| Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist S Feng, M Yang, Z Zhang, Z Wang, D Hong, H Richter, GM Benson, ... Bioorganic & medicinal chemistry letters 19 (9), 2595-2598, 2009 | 58 | 2009 |
| An enzyme‐labile safety catch linker for combinatorial synthesis on a soluble polymeric support U Grether, H Waldmann Angewandte Chemie International Edition 39 (9), 1629-1632, 2000 | 51 | 2000 |
| Selective cannabinoid 2 receptor agonists as potential therapeutic drugs for the treatment of endotoxin-induced uveitis RF Porter, AM Szczesniak, JT Toguri, S Gebremeskel, B Johnston, ... Molecules 24 (18), 3338, 2019 | 48 | 2019 |
| Development of the Traceless Phenylhydrazide Linker for Solid‐Phase Synthesis F Stieber, U Grether, H Waldmann Chemistry–A European Journal 9 (14), 3270-3281, 2003 | 46 | 2003 |
Bernd KuhnF. Hoffmann-La RocheVerifisert e-postadresse på roche.com